Having Severe Hypertriglyceridemia: Lower Triglycerides & Improve Liver Health with Pegozafermin

Please fill in your details

Please enter first name.

Please enter last name.

Please enter valid email.

Please enter valid contact number.

Please select type of diabetes.

About the Study

This study is for individuals with very high levels of triglycerides (a type of fatty substance in the blood). This is called severe hypertriglyceridemia. Individuals are thought to have this condition when their blood triglyceride levels are above 500 mg/dL.

Participants in this study will start taking either a once-weekly investigational injection or placebo. The investigational med is called pegozafermin and is currently not approved by the FDA. In previous studies, Pegozafermin has shown the ability to lower blood triglycerides and decrease abnormal fat storage in the liver. Participants have a 75% chance of receiving pegozafermin or a 25% chance of receiving placebo.

The purpose of this study is to learn about the safety and effectiveness of the research drug on triglyceride levels, cholesterols, fatty proteins, blood sugars, and organs like the liver.

Participant Eligibility Criteria ( To take part in the study )